Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference January 30, 2023 • 8:00 AM EST
Kintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023 January 9, 2023 • 8:30 AM EST
Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) December 15, 2022 • 8:00 AM EST
Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022 December 1, 2022 • 8:00 AM EST
Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement November 30, 2022 • 8:00 AM EST
Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer November 28, 2022 • 8:00 AM EST
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting November 18, 2022 • 8:00 AM EST
Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update November 9, 2022 • 5:20 PM EST
Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study October 19, 2022 • 8:15 AM EDT